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CD22 is a B cell-specific member of the immunoglobulin superfamily and binds to sialic acid.
CD22 inhibits B cell receptor signaling. Mice deficient for CD22 show a largely normal B cell
development. Here, we have performed a detailed analysis of the splenic B cell population
and found that the subset of marginal zone (MZ) B cells was selectively reduced in CD22-
deficient mice. CD22-deficient mice showed a lack of TNP-ficoll capturing cells in the MZ
and a reduced response to TNP-ficoll, particularly when the antigen was applied intrave-
nously. CD22-deficient B cells showed both enhanced motility as well as enhanced chemo-
taxis to certain chemokines. The altered chemokine responsiveness or the higher signaling
capacity of CD22-deficient B cells may lead to the compromised MZ B cell compartment, as
both processes have previously been shown to affect MZ composition.
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1 Introduction
CD22 is a B cell specific transmembrane protein. It is a
member of the siglec (sialic acid binding immunoglobulin-
like lectins) family of adhesion receptors that bind specifi-
cally to sialic acids [1]. CD22 acts as a negative regulator
of B cell receptor (BCR) signaling [2, 3]. Upon engage-
ment of the BCR CD22 is phosphorylated on tyrosines on
its intracellular tail [4, 5]. Tyrosine phosphorylation of the
immunoreceptor tyrosine-based inhibition motifs (ITIM) of
CD22 leads to recruitment and activation of SHP-1 which
is the most important factor binding to the CD22 tail [4].
The negative role of CD22 in BCR signaling has been clar-
ified by generation of CD22-deficient mice. When B cells
of these mice were stimulated with anti-IgM they showed
a highly increased Ca2+ response [2, 3, 6–8]. B cell devel-
opment in CD22-deficient mice was relatively normal with
the exceptions of a mildly preactivated B cell phenotype
in the spleen and a homing defect of mature recirculating
B cells to the bone marrow [3, 6–8]. When CD22-deficient
mice were challenged with a T cell-dependent antigen
they showed a normal response, accompanied by normal
germinal center formation [3, 7]. However, the thymus-in-
dependent type II (TI-2) response to TNP-ficoll was
reduced [3, 7]. This seemed to be in contradiction to the
enlarged Ca2+ response of CD22-deficient B cells.
Impairment of the TI-2 response could be caused by
either a functional alteration of CD22–/– B cells or by the
lack of the cellular population responsible for this
response. TI-2 responses are mainly performed by B1 B
cells and marginal zone (MZ) B cells [9, 10]. Since B1 B
cells occur in normal numbers in CD22-deficient mice
we therefore analyzed here their MZ B cell population.
MZ B cells represent a distinctive subset of B lympho-
cytes. They are exclusively located in the periphery of the
splenic periarteriolar lymphoid sheath (PALS), at the bor-
der of white and red pulp [11–13]. In addition to this spe-
cific localization, they can be distinguished from follicu-
lar, recirculating B cells by the characteristic expression
of cell surface markers. MZ B cells are described as IgM-
highIgDlowCD21highCD23low/negCD1high, while follicular B cells
are mainly IgMlowIgDhighCD21medCD23high CD1neg [10, 12,
14–16]. These cells have a preactivated phenotype. They
express high levels of B7–1 and B7–2 and upon stimula-
tion with polyclonal activators they differentiate into
plasma cells in a matter of hours [16]. This preactivated
state and their localization adjacent to the marginal
sinuses are critical for the proposed function of these
cells. MZ B cells are among the first population of cells to
“see” blood-borne antigens and recent experiments
revealed that they play a critical role in host defense
against bacterial pathogens [13].
The mechanisms governing the differentiation of MZ B
cells have only recently been investigated. Several gene-
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Fig. 1. CD22-deficient mice show an impaired response to
i.p. or i.v. injected TNP-Ficoll. Five wild-type and five CD22-
deficient mice (CD22–/–) were immunized with 10 ? g TNP-
Ficoll, either i.p. (top) or i.v. (bottom). TNP-specific IgG3 of
day 5 and day 7 (d5, d7) was measured in ELISA and is
shown here because it is the typical TI-2 IgG isotype with the
highest induction. Anti-TNP IgM was also reduced, however,
less pronounced (not shown). Means with standard devia-
tion are given. *, p X 0.05; **, p X 0.01 in Student’s t-test. One
typical result of three experiments is shown.
deficient mice, such as Pyk-2–/– mice, Lsc–/– mice,
Aiolos–/– mice, NF- ‹ B p50–/– and RelB–/– mice, have a
reduced MZ B cell compartment [17–21]. Other gene-
deficient mice such as BTK–/– or CD21–/– mice have pro-
portionally increased MZ B cell numbers [18, 22]. One of
the hypotheses derived from the analysis of these differ-
ent genetically modified mice was that depending on the
strength of the signal elicited at the BCR, differentiation
to follicular or MZ B cells is affected. This model sug-
gests that a strong signal will favor follicular B cell devel-
opment (and perhaps B1 B cell development), whereas a
weak signal will promote differentiation towards the MZ
B cell direction [18, 22–24]. Transgenic systems have
also shown that the specificity of the expressed BCR can
bias B cell differentiation into the B2, B1 or MZ lineage
[13, 23]. Here we have analyzed MZ B cells in CD22-
deficient mice and find that their numbers are reduced
which fits to the proposed signal strength model.
2 Results
2.1 CD22-deficient mice show an impaired
TI-2 response
To extend our previous findings, CD22–/– mice and wild-
type control mice were immunized with TI-2 antigen
TNP-ficoll in two different routes. CD22–/– mice show a 2-
fold lower response to TNP-ficoll, as compared to wild
type mice, when the antigen was injected i.p. (Fig. 1), as
previously shown [3, 7]. However, when the same anti-
gen dose was applied i.v., the response was more
impaired (three- to fourfold lower than control mice;
Fig. 1). Similarly, the response of CD22–/– mice to i.p
injected Pneumovax, a different TI-2 antigen, was also
reduced two-fold compared to wild-type mice (not
shown). Since MZ B cells are involved in early B cell
responses, particularly to blood-borne antigens, this
result suggested that the MZ B cell compartment could
be affected in CD22–/– mice.
2.2 The number of MZ B lymphocytes is reduced
in CD22–/– mice
To investigate whether CD22 deficiency affects the size
of the MZ B cell compartment, we performed flow
cytometry analyses of splenocytes isolated from wild-
type and CD22–/– mice. Analysis of cell surface expres-
sion of CD21 and CD23 on the B cell population (B220/
CD45R+ cells) allowed us to discriminate between newly
formed (or transitional, T1) B cells (CD21neg/CD23neg), fol-
licular, recirculating B cells (CD21med/CD23high) and MZ B
cells (CD21high/CD23low/neg) (Fig. 2A). While proportions of
newly formed and follicular B cells appeared similar in
both wild type and CD22–/– splenocytes, significant
reduction of MZ B cells in CD22–/– animals was observed
(Fig. 2A). Independent examination of ten animals of
both wild-type and CD22–/– genotype confirmed that
CD22 deficiency leads to reduction of MZ B cells in the
range of three- to fourfold. This phenotypic defect was
further confirmed by demonstrating the absence of
CD21high and CD1high cells within the IgMhigh/IgDlow popu-
lation in CD22–/– animals (Fig. 2B). We checked the
expression of activation markers in the remaining MZ B
cell population as well as in the follicular B cells in CD22-
deficient mice. In both B cell populations expression lev-
els of MHC class II, B7.2 and CD69 were identical
between wild-type and CD22–/– mice (data not shown).
This shows that there is not a gross difference in the acti-
vation state of remaining MZ B cells in the CD22 defi-
cient animals.
Histological examination of wild-type and CD22–/– mice
showed a clear difference in splenic architecture. In wild-
type mice a characteristic rim of IgM positive cells was
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Fig. 2. CD22 deficiency impairs marginal zone B cells devel-
opment. (A) Splenocytes isolated from wild-type and
CD22–/– mice were stained with a combination of anti-B220,
anti-CD21 and anti-CD23 antibodies. Within the B220+ cell
gate, marginal zone (MZ), follicular (FO) and newly formed
(NF) B cells are indicated. Mean percentages of MZ B cells
with standard deviation out of ten analyzed animals of both
genotypes are given. (B) Wild-type and CD22–/– splenocytes
were stained with anti-IgM, anti-IgD and anti-CD21 or anti-
CD1 antibodies. Histograms show CD21 or CD1 staining of
IgMhighIgDlow gated splenocytes. CD21 high and CD1 high
cells from this gate are MZ B cells.
Fig. 3. Alteration of spleen architecture in CD22–/– mice.
Spleen sections (4 ? m thick) from wild-type and CD22–/–
mice were stained with combination of PE-labeled anti-IgM
(red) and FITC-labeled anti-MOMA-1 (green) antibodies.
Representative results obtained from spleen sections of
seven animals in each group are shown. Sections were
viewed under 400x magnification.
located at the periphery of the follicles and separated by
metallophilic (MOMA-1 positive) macrophages. These B
cells are MZ B cells. This B cell population was signifi-
cantly reduced in the spleens of CD22–/– animals (Fig. 3).
These data confirm in situ the physical disappearance of
MZ B cells, which was also observed in cytometric analy-
sis.
2.3 TNP-Ficoll capturing is reduced in
CD22–/– mice
It has been shown that intravenously injected TNP-Ficoll
is initially specifically captured by marginal zone but not
follicular B cells [9, 17, 20]. Wild-type and CD22–/– mice
were injected i.v. with TNP-Ficoll and after 30 min
spleens were examined for the presence of antigen using
TNP-specific antibody. In agreement with previously
reported data in wild-type mice binding of anti-TNP anti-
body was associated with the CD21high/CD23low/neg (MZ)
population of splenic B cells (Fig. 4A) and localized out-
side of the metallophilic macrophage rim (Fig. 4B). In the
gate of follicular and newly formed B cells no significant
capturing of antigen was observed (data not shown). In
contrast to wild-type mice, capture of TNP-Ficoll was
significantly reduced in CD22–/– mice as established by
cytometric (Fig. 4A) as well as by histological examina-
tion (Fig. 4B).
2.4 CD22-/- splenocytes show altered migration
Recent data suggest that chemotactic responses play an
important role in B cells compartmentalization [19–21,
25–28]. To address the question whether CD22 defi-
ciency affects the ability of B cells to migrate, we com-
pared the migration of wild type and CD22–/– B cells in
the presence or absence of chemokines. This analysis
revealed that residual MZ B cells have increased migra-
tion ability, although the number of MZ B cells is reduced
in CD22-deficient mice. The percentage of CD22–/– MZ B
cells that migrated in the absence of chemokines was
significantly higher compared to wild-type cells (Fig. 5).
The migration pattern differences between wild type and
Eur. J. Immunol. 2002. 32: 561–567 Marginal zone B cells in CD22–/– mice 563
Fig. 4. T cell-independent type II antigen capturing in wild-
type and CD22–/– mice. TNP-Ficoll (100 ? g) was injected
intravenously in wild-type and CD22–/– mice. After 30 min,
animals were sacrificed and spleens were used for FACS
and immunohistological examination. As a control we used
unimmunized animals of the corespondent genotypes. (A)
Splenocytes were stained with combination of anti-B220,
anti-CD21, anti-CD23 and anti-TNP Ab. Marginal zone B
cells (B220+CD21highCD23low) were gated and histograms
presenting anti-TNP staining of immunized and unimmu-
nized animals are shown. Data are representative out of
four sets of experiments. (B) Spleen sections from TNP-
Ficoll immunized animals were stained with biotin-labeled
anti-TNP (red) and FITC-labeled anti-MOMA-1 (green) anti-
bodies. Biotinylated antibody was revealed with
streptavidin-Cy-Chrome. Sections were mounted with
Moviol containing DNA-specific fluorescent dye DAPI (blue),
which stained all nucleated cells. Sections were viewed
under 400x magnification.
CD22–/– B cells were further potentiated in the presence
of MIP-3 g and SDF-1 § , while in the case of BLC-
stimulated cells no further difference was observed. A
similar migration pattern was observed for follicular and
newly formed B cells (Fig. 5), indicating that generally
CD22 deficient B cells have a higher migration property.
3 Discussion
In this study we have demonstrated for the first time that
CD22-deficient mice have a specific defect in marginal
zone B cell numbers. Flow cytometric analysis revealed
that proportion of CD21highCD23low/negCD1highIgMhighIgDlow
cells (MZ B cells) is three- to fourfold reduced in CD22–/–
mice, while other splenic compartments (follicular and
newly formed) appear normal. The obtained results can
not be attributed to the alteration in surface marker
expression since histological analysis show physical loss
of IgM+ cells in the PALS. Furthermore, examination
based on T-independent antigen (TNP-Ficoll) binding
and humoral response to the same prove impaired mar-
ginal zone B cells function in CD22–/– mice.
The obvious question is the mechanism by which CD22
deficiency affects marginal zone B cell composition.
Several recent papers suggested that the strength of the
signal elicited at the B cell receptor affects MZ B cells
development [17, 22–24]. This hypothesis predicts that
weak signals favor the differentiation of MZ B cells,
medium signals give rise to follicular B cells and strong
signals induce differentiation of B1 cells. It was shown
that B cells in Aiolos–/– mice, which have reduced MZ B
cells, have an increased calcium influx upon BCR stimu-
lation [18]. In contrast, marginal zone B cell numbers are
increased in BTK-deficient mice, where BCR signal
strength is reduced [18, 22]. It is well-documented that
stimulation of CD22-deficient B cells results in an
enhanced calcium influx [2, 3, 6–8]. Regarding these
data, the observed reduction of MZ B cells in CD22–/–
mice support the hypothesis that increased signal
strength upon stimulation leads to impaired MZ B cell
compartment.
A reduced MZ B cell compartment could be caused by
defective development of MZ B cells, defective migration
or defective retention at the correct microenvironmental
site. There is good evidence that proper B cell compart-
mentalization depends on cell motility and chemotactic
response [19–21, 25–28]. MZ B cells show a highly
motile behavior, as was shown by in vivo application of
the G § i inhibitor pertussis toxin. This substance which
inhibits all known chemokine receptor signals depleted
MZ B cells within 48 h without affecting follicular cells
[20]. Recently it has been shown that impaired MZ B cell
development in Pyk–2–/–, Lsc–/– and Dock2–/– mice is
associated with altered motility [19, 20, 29]. Therefore, it
was reasonable to assume that CD22 deficiency may
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Fig. 5. Altered migration of CD22–/– splenocytes. Migration of lympholyte-M purified splenocytes (106) from wild-type and CD22–/–
mice were analyzed. Cells placed in 5- ? m pore-size transwell insert were incubated 4 h at 37oC in the gradient of 0.1 ? g SDF-1 § ,
1 ? g/ml BLC or 0.5 ? g/ml MIP-3 g . After incubation, migrated cells were harvested, stained with anti-B220, anti-CD21 and anti-
CD23 antibodies, counted and analyzed by flow cytometry. Data present mean percentage of migrated cells from indicated B cell
compartments obtained by analysis of three animals/group.
also lead to altered cell migration. Indeed, we observed
that basal motility of CD22-deficient B cells is signifi-
cantly increased compared to wild-type B cells. Surpris-
ingly, while examination of B cell migration in the pres-
ence of MIP-3 g and SDF-1 § showed increase in CD22–/–
mice, no additional increase in motility was observed in
response to BLC.
How the lack of CD22 influences chemokinesis is not
known. Principally, CD22 could act indirectly on chemo-
kine signaling by changing the signaling threshold. It was
shown that BCR engagement changes the chemokine
responsiveness [30]. Since CD22–/– B cells are in a preac-
tivated state this may easily account for altered respon-
siveness, for example by a changed chemokine receptor
expression pattern. In this respect it is relevant that defi-
ciency of lyn, the kinase responsible for CD22 phosphory-
lation and SHP-1 recruitment, causes loss of MZ B cells
and shows also, when crossed to an Ig transgenic mouse,
a higher responsiveness to MIP3 g [31].
Alternatively, CD22 could directly inhibit chemokine signal-
ing by a yet undefined mechanism. Engagement of che-
mokine receptors has been shown to activate Pyk-2, an
intracellular tyrosine kinase that is important for MZ B cells
[20, 32, 33]. It was demonstrated that by activating the
chemokine receptor CCR5, SHP-1 is activated and binds
to Pyk-2 [32]. Also, SHP-1 deficient hematopoietic cells
from motheaten mice show enhanced chemotactic
responses [34]. Since CD22 is a major activator of SHP-1
in B cells after BCR engagement, this activation may
directly inhibit chemokine receptor signaling. However,
specific experiments are needed to test these possibilities.
Since CD22 is an adhesion molecule and has an impor-
tant role in bone marrow homing of mature lymphocytes it
is also possible that the reduction of MZ B cells in
CD22–/– mice is due to impaired homing to the MZ. We
previously analyzed histological sections of various
organs for expression of § 2,6-linked sialic acid, the ligand
of CD22. We observed specific expression on the endo-
thelium only in the bone marrow, but not on endothelial
cells of the spleen or lymph node [35]. Therefore, we con-
sider a homing defect to the MZ as a less likely explana-
tion for the loss of MZ B cells in CD22-deficient mice.
There is good evidence that thymus-independent im-
mune responses of the TI-2 type are made by B1 cells,
the class of B cells found mainly in the peritoneum, and
by MZ B cells of the spleen [9, 13]. These cells are the
main cells which generate a primary IgM and IgG3
response to bacterial antigens. The role of MZ versus B1
cells in the TI-2 response has recently been studied by a
transgenic model in which MZ or B1 cells could be fol-
lowed histochemically or in FACS by use of anti-idiotypic
antibodies [13]. This study has demonstrated that the
route of antigen application as well as the BCR specific-
ity determines the relative contribution of these two B
cell compartments to the response. MZ B cells are par-
ticularly involved in response to blood borne antigens,
which is to be expected because of their location next to
the marginal sinus in the spleen. The knockout of various
genes which are expressed in B cells has led to impaired
TI-2 responses of the deficient mice. Some of these,
such as BTK–/– or Vav1–/– have a reduced B1 compart-
ment, while others, such as Pyk2–/–, Lsc–/– or Dock2–/–
mice have a compromised MZ B cell compartment.
However, since some of these mice also show impaired
cellular signaling, it is not clear to what extend just the
loss of a certain B cell population can serve as an expla-
nation for the impaired immune response.
CD22 deficiency does not lead to impaired B cell signal-
ing, but rather to an enhanced response. This together
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with the presence of normal [3, 7] or even increased [6, 8]
B1 cell numbers suggests that the strong reduction of
MZ B cells in CD22-deficient mice may explain their
impaired TI-2 response. Our findings that the i.v. route of
antigen application leads to stronger reduction in
response than the i.p. route does, could be taken as evi-
dence for this mechanism. However, alternative explana-
tions for the impaired TI-2 response, such as a stronger
apoptosis induction in CD22-deficient B cells by anti-
gens such as TNP-ficoll, can not be fully excluded.
In summary, we have shown that CD22-deficient mice
have a reduced MZ B cell compartment. Their B cells are
less able to bind TNP-ficoll and to trigger TI-2 immune
responses. Also, CD22–/– B cells show enhanced chemo-
taxis which may affect the recruitment or retention in the
MZ compartment.
4 Materials and methods
4.1 Mice
C57BL/6 wild-type and CD22-deficient mice on the same
genetic background were obtained from our breeding facil-
ity. Mice were analyzed between 8–10 weeks after birth.
4.2 Immunizations
CD22–/– or wild-type control mice were immunized with
10 ? g TNP-Ficoll (Biosearch Technologies, Novato, CA) and
bled on day 0, day 5 and day 7. The TNP-specific antibodies
in the sera were determined by ELISA with TNP-BSA-coated
polysorb plates (Nalge Nunc, Rochester, NY). Sera were
applied in serial dilutions on the plates and IgM or IgG3 was
measured by use of goat-anti IgM or anti-IgG3 alkaline
phosphatase-labeled antibodies (Southern Biotechnologies)
and the substrate p-nitrophenyl phosphate (Sigma). One
pool of sera, applied to all plates, served as an internal stan-
dard defining arbitrary units. Alternatively mice were injected
intravenously with 100 ? g of TNP-Ficoll. At 30 min after
injection, mice were sacrificed and spleens were taken out.
One half of the spleen was used for histological examina-
tions while the other half was used for FACS analysis.
4.3 Flow cytometry analysis
Single-cell suspensions of Lympholyte-M (Cederlane, Labo-
ratories Ltd, Ontario, Canada) purified splenocytes (5×105)
were incubated for 30 min at +4oC with different combina-
tions (as indicated in the results section) of the following
antibodies: anti-B220-biotin, anti-CD21-FITC, anti-CD23-
PE, anti-IgM-PE, anti-IgD-biotin, anti-CD1-FITC, anti-MHC
class II-FITC, anti-CD69-biotin, anti-B7.2-FITC and anti-
TNP-biotin (all produced by Pharmingen, San Diego, CA).
Stainings were performed in PBS containing 0.1% BSA
(Roche Diagnostics, Mannheim, Germany), 0.1 % Na-azide
and saturating concentration of anti-CD16/CD32 (Pharmin-
gen) to block Fc + III/II receptors. Biotin-labeled antibodies
were revealed by Streptavidin-Cy-Chrom (Pharmingen). Cell
surface marker expression was analyzed using a four-color
flow cytometer (FACScalibur) and Cell Quest Software (Bec-
ton Dickinson, Heidelberg, Germany).
4.4 Immunohistochemistry
Spleens were embedded in Tissue-Tek O.C.T. compound
(Sakura, The Netherlands), snap-frozen in liquid nitrogen
and stored at –80oC. Cryostat sections of 4 ? m were pre-
pared, air dried, and fixed in acetone (10 min at room tem-
perature). Slides were incubated 45 min with staining buffer
(PBS containing 0.1% BSA, 0.1% Na-azide and anti-CD16/
CD32 followed by staining for 45 min with 1:100 dilution of
both anti-IgM-PE and MOMA-1-FITC (Serotec, GB). Sec-
tions from TNP-Ficoll-treated animals were stained with
combination of anti-TNP-biotin and MOMA-1-FITC anti-
bodies. Biotinylated antibodies were revealed with
streptavidin-Cy-Chrom (1:100) and slides were mounted in
Moviol containing DAPI (0.1 ? g/ml) (Roche). Slides were
analyzed using a Leica microscope (DMIRB/E) and OpenLab
software (version 2.2.5). The excitation wavelength for FITC
was 494 nm, for PE 576 nm, for Cy 581 nm, and for DAPI
excitation wavelength was 359 nm.
4.5 Migration assay
Lympholyte-M purified splenocytes (106) were assayed for
transmigration using 5- ? m pore-size transwell culture
inserts (Costar, GB). The medium used for the experiments
was RPMI 1640 supplemented with 0.25 % fatty-acid free
BSA (Sigma). To assay chemotaxis, the bottom chambers
were filled with 1 ? g/ml of MIP-3 g , 0.5 ? g/ml of BLC or
0.1 ? g/ml of SDF-1 § (all from R&D). The migration occurred
at 37oC in a humidified atmosphere with 5% CO2 over 4 h.
After incubation, cells which had migrated to the lower
chamber were harvested, stained with anti-B220-PerCP
(Pharmingen), anti-CD21-FITC, and anti-CD23-PE, and
counted by FACScalibur and analyzed by CellQuest soft-
ware.
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